Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Actelion and J&J Re-Enter Negotiations

By Mike Botta | December 22, 2016

Actelion announced yesterday that it has re-entered negotiations with Johnson & Johnson regarding a “possible strategic transaction.”

Johnson & Johnson had approached the Swiss drugmaker in November in a reported takeover bid, but talks were said to have broken off early last week. Earlier this month, Sanofi also reportedly was considering a counter-bid, but J&J remained interested in reaching a deal before Christmas, according to Bloomberg, which quoted a source as saying that “J&J raised its bid above $250 a share … which would value Actelion at more than $27 billion.”

Actelion is a $17 billion biotech company focused largely on pulmonary arterial hypertension (PAH) medication with a portfolio of oral, inhaled and intravenous treatments.

The company targets a range of disorders around the globe, including Type 1 Gaucher disease, Niemann-Pick type C disease, Digital Ulcers in patients suffering from systemic sclerosis, and mycosis fungoides in patients with cutaneous T-cell lymphoma.

Actelion reported yesterday that “there can be no assurance any transaction will result from these (latest) discussions,” adding that the company “does not intend to make any additional comments regarding these discussions unless and until it is appropriate to do so, or a formal agreement has been reached.” 

Founded in late 1997, Actelion is headquartered in Allschwil/Basel, Switzerland and serves global markets including including Europe, the U.S., Japan, China, Russia and Mexico.

(Source: Actelion Ltd.)


Filed Under: Drug Discovery

 

Related Articles Read More >

Pharmacovigilance
A new era of pharmacovigilance: Worldwide master key for drug safety monitoring
Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50